Reports Q3 revenue $211.0M, consensus $175.52M. Cash, cash equivalents, and marketable securities were $1.687B as of September 30, compared to $1.139B as of December 31, 2024. “We achieved an outstanding quarter, highlighted by the strong start to the global Sephience launch,” said Matthew B. Klein, CEO. “The broad initial uptake supports the potential of Sephience to become the standard of care for all individuals with PKU, as well as the foundational product for PTC’s sustained growth and success.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- Truist sees no read-throughs to PTC, Wave Life from uniQure news
- PTC Therapeutics price target raised to $77 from $63 at Jefferies
- PTCT Upcoming Earnings Report: What to Expect?
- PTC Therapeutics price target raised to $87 from $76 at BofA
- Optimistic Buy Rating for PTC Therapeutics Driven by Strong Demand and Promising Sales Projections for Sephience